Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
First Claim
Patent Images
1. A method of improving function and structure of the vascular system of a human host, said method comprising:
- administering orally to said host in accordance with a predetermined regimen a prophylactic dose of a source of at least one of L-arginine and L-lysine as other than a natural food source to enhance the level of endogenous NO in the vascular system to improve vascular function.
0 Assignments
0 Petitions
Accused Products
Abstract
Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes.
5 Citations
21 Claims
-
1. A method of improving function and structure of the vascular system of a human host, said method comprising:
administering orally to said host in accordance with a predetermined regimen a prophylactic dose of a source of at least one of L-arginine and L-lysine as other than a natural food source to enhance the level of endogenous NO in the vascular system to improve vascular function. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16)
-
13. A method of preventing a reduction in vascular function of the vascular system of a human host as evidenced by reduced vasodilation, said method comprising:
-
administering orally to said human host in accordance with a predetermined regimen a prophylactic dosage of at least one of L-arginine, L-lysine or physiologically acceptable salt thereof as other than a natural food source in a daily amount to provide a plasma level in the range of 0.15 to 3 mM to enhance the level of endogenous NO in the vascular system, whereby reduction in said vasodilation is inhibited.
-
-
17. A physiologically acceptable formulation comprising at least one of L-arginine, L-lysine or its physiologically acceptable salt in from about 0.5 to 5 g and at least one of calcium, folate, B6, or B12, in sufficient amount to enhance the effect of said L-arginine, L-lysine or its physiologically acceptable salt on enhancing the amount of NO in a human host.
-
18. A physiologically acceptable formulation comprising L-arginine or its physiologically acceptable salt.
-
19. A physiologically acceptable formulation comprising L-lysine or its physiologically acceptable salt.
-
20. A method for inhibiting vascular smooth muscle cell proliferation at a site of injury in the vascular system, said method comprising:
-
administering at said site an effective amount of at least one of L-arginine, L-lysine or its physiologically acceptable salt to enhance NO production;
whereby vascular smooth muscle cell proliferation is inhibited. - View Dependent Claims (21)
-
Specification